company background image
GENE logo

Genetic Technologies NasdaqCM:GENE Stock Report

Last Price

US$0.77

Market Cap

US$3.6m

7D

0%

1Y

-70.0%

Updated

18 Dec, 2024

Data

Company Financials

Genetic Technologies Limited

NasdaqCM:GENE Stock Report

Market Cap: US$3.6m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

GENE Stock Overview

A molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people’s health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. More details

GENE fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Genetic Technologies Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Genetic Technologies
Historical stock prices
Current Share PriceAU$0.77
52 Week HighAU$3.59
52 Week LowAU$0.67
Beta0.46
1 Month Change0%
3 Month Change-6.14%
1 Year Change-70.02%
3 Year Change-93.05%
5 Year Change-91.72%
Change since IPO-99.91%

Recent News & Updates

Recent updates

Genetic acquires AffinityDNA to bolster direct-to-consumer business

Jul 14

Infinity Biologix launches Genetic Technologies' COVID-19 test

Jun 09

Genetic Technologies launches COVID-19 risk test through partnership with Infinity Biologix

Jun 01

Genetic Technologies’ COVID-19 risk test to be commercially available in U.S.

Apr 26

Genetic Technologies appoints new CEO; Shares are up 8%

Jan 04

Shareholder Returns

GENEUS Life SciencesUS Market
7D0%2.1%0.7%
1Y-70.0%-19.1%8.1%

Return vs Industry: GENE underperformed the US Life Sciences industry which returned -3.7% over the past year.

Return vs Market: GENE underperformed the US Market which returned 26.1% over the past year.

Price Volatility

Is GENE's price volatile compared to industry and market?
GENE volatility
GENE Average Weekly Movementn/a
Life Sciences Industry Average Movement9.4%
Market Average Movement6.4%
10% most volatile stocks in US Market17.2%
10% least volatile stocks in US Market3.2%

Stable Share Price: GENE's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine GENE's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
198755Kevin Camillerigenetype.com

Genetic Technologies Limited, a molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people’s health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company operates through EasyDNA, AffinityDNA, and GeneType/Corporate segments. It offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer.

Genetic Technologies Limited Fundamentals Summary

How do Genetic Technologies's earnings and revenue compare to its market cap?
GENE fundamental statistics
Market capUS$3.58m
Earnings (TTM)-US$7.59m
Revenue (TTM)US$6.11m

0.6x

P/S Ratio

-0.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GENE income statement (TTM)
RevenueAU$9.67m
Cost of RevenueAU$3.76m
Gross ProfitAU$5.91m
Other ExpensesAU$17.93m
Earnings-AU$12.02m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.083
Gross Margin61.12%
Net Profit Margin-124.24%
Debt/Equity Ratio35.2%

How did GENE perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 08:50
End of Day Share Price 2024/10/16 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Genetic Technologies Limited is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Marc KennisAPP Securities Pty Ltd.
Kevin DeGeeterLadenburg Thalmann & Company
Chris KallosMST Financial Services Pty Limited